Tag: Jazz Pharmaceuticals

First Dual-Acting DNRI to Treat Daytime Sleepiness Approved by FDA

Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) approved Sunosi™ (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associate...

Jazz Pharmaceuticals and Codiak to R&D Cancer Treatment

Jazz Pharmaceuticals plc and Codiak BioSciences, Inc. announced that the companies have entered into a strategic collaboration agreement focused on the research, development and commercialization of e...

Vyxeos obtained marketing authorisation in Europe

Jazz Pharmaceuticals announced that the European Commission approved Vyxeos® 44 mg/100 mg powder for concentrate for solution for infusion.

Jazz Pharmaceuticals and MD Anderson Cancer Center entered into collaboration

Jazz Pharmaceuticals and The University of Texas MD Anderson Cancer Center announced a five-year collaboration agreement with a goal of evaluating therapies for multiple hematologic malignancies.